By By Michael Braunagel, managing director, Actigen
Enzyme replacement therapy (ERT) made its debut in 1991, heralding a breakthrough in medical science for individuals and families grappling with rare diseases stemming from single gene mutations.
The report compiles several of the key factors that are driving the growth of antimicrobial resistance, highlighting the pharmaceutical industry as a key economic sector driving the issue.
US FDA approves Fetroja, an antibiotic developed by Shionogi, for the treatment of complicated urinary tract infections, as part of the effort to fight AMR.
Research has discovered that bacteria will open holes in their cell wall under certain conditions, potentially leading to a new drug target or greater potency of existing antibiotics.
Sanofi and IONTAS have signed an agreement through which the company will use IONTAS’ proprietary technology – which aims to bridge the gap between a “great lead” and “poor developability,” says CBO.
Research looks to microneedle patch to combat antimicrobial resistance
A skin patch designed to deliver antibiotics directly into the bloodstream could prevent the development of antimicrobial resistance in gut bacteria, say scientists in Ireland.
Fraunhofer is “redoubling” its efforts to develop new antibiotics and transfer research into clinical trials through a project available to external partners for development.
CMC Biologics and Trellis Bioscience have entered into a manufacturing agreement for the process development and production of two of Trellis’ monoclonal antibodies (mAbs).
The EMA says aligning antibiotic trial requirements with the US FDA and Japan’s PMDA should allow drug firms to conduct single global development programmes.
Regulators in Europe, Japan and the US say they have aligned clinical data requirements for new antibiotics to encourage industry to develop drugs for infections caused by resistant bacteria.
The Novo Nordisk Foundation has awarded a DKK118m ($17m) grant to fund development of a fermentation pilot plant for cell line scale up experiments at the Technical University of Denmark.
Charles River Laboratories has announced an "end-to-end" service offering of CRISPR/Cas9 genome engineering technology, including custom in vivo and in vitro genome editing.
Phages, peptides and live biotherapeutics could help combat antibiotic-resistant bacteria but don’t expect heavy R&D investment until people start dying from post-operative infection, says EpiBiome.
Compounds that leave pathogenic bacteria alive but harmless could yield antibiotics that are less likely to induce resistance development say the authors of a new study.
International Chemical Investors Group (ICIG) and Novartis Group have entered into an agreement in which ICIG will acquire all shares in Sandoz Industrial Products GmbH.
Bacterial resistance to ciproflaxin is spreading according to the European CDC which wants the drug industry to invest in development of alternatives to the "last resort" antibiotic.
Sterigenics will triple gamma sterilisation capacity at a site in Arkansas on the back of strong demand from pharmaceutical and medical device customers.
As the US regulator awards iclaprim expedited QIDP status, a former FDA antibiotics expert says the scheme boosts antibiotics without enough evidence for efficacy.
Contract research organization Charles River Laboratories has extended its initial three-year strategic partnership with AstraZeneca for an additional five years.
Thermo Fisher Scientific has developed new software via a partnership with the Special Bacteriology Reference Laboratory at the CDC (Centers for Disease Control and Prevention) that helps public health labs to more quickly identify microbial pathogens...
AstraZeneca will spend $40m spinning out its antibiotics R&D business into a separate subsidiary, saying the move will let it focus on its core disease areas.
Drug industry execs at the World Economic Forum in Davos, Switzerland were told they are no longer best placed to develop antibiotics by a panel who said Governments should lead efforts to create these vital new drugs.
Discovering a new antibiotic candidate and finding out how it kills superbugs without letting resistant mutants escape involved advanced chemistry according to the scientists who determined its structure.
Horizon Discovery says the gene editing tool CRISPR used to engineer its human cell lines is exploding the possibilities of screening for preclinical customers.
Scientists are scouring the seas for novel bioactive compounds as part of PharmaSea, a four-year project which has already turned up interesting compounds from samples of mud, sediment and sea life.
Higher earnings and improved margins did not impress investors in Lonza, which saw its share price tumble today after revealing that sales to the drug sector fell in 2013.
Early stage drug developer Charles River Laboratories is pushing further into Asia with its purchase of the microbiology subcontractor BRASS Pte Ltd. Terms of the acquisition were not disclosed.
US scientists have claimed that ‘bacterial autopsies’ could accelerate the discovery of new antibiotics in an announcement made just days after the US CDC warned of a potential “post-antibiotic era” and called for renewed development efforts.
German CRO Evotec and the Harvard Stem Cell Institute have partnered to discover compounds that might prevent or slow ALS (amyotrophic lateral sclerosis) and other motor-neuron diseases.
Lonza has granted access to its potency boosting expression system to antibody developer Sorrento Therapeutics just days after a signing a similar deal with Pfizer.
In a rare move, the FDA has publically released Alexion Pharmaceuticals’ response to a Form 483 following inspection of its US site and the discovery of microbial contamination.
French CMO Indicia production says the acquisition of Biotechnologie Appliquee will strengthen its ready-to-use media manufacturing and add R&D capabilities to its offerings.
